Table of Contents
National Immunization Survey-Child (NIS-Child) 2020, Texas
Immunization Coverage Among
Texas Children at 24 Months of Age
Source:
CDC
NIS-Child Report
About
the National Immunization Survey-Child (NIS-Child)
The National Immunization Survey–Child (NIS-Child) is
conducted annually by the Centers for Disease Control and Prevention (CDC) to
assess immunization coverage (percent of the population vaccinated) among young
children.
The
NIS is the only population-based survey to provide national, state, local area,
and territorial estimates of vaccination coverage among children in the United
States. This study collects data by administering telephone surveys to randomly
selected households. To ensure the accuracy and precision of the vaccination
coverage estimates, immunization data for surveyed children are also collected
through a mail survey of their pediatricians, family physicians, and other
health care providers. The parents and guardians of eligible children are asked
during the telephone interview for consent to contact the children’s
vaccination providers. Data are weighted to be representative of the population
of children 24 months of age, and are adjusted for multiple phone lines, mixed
telephone lines (i.e., landline and cellular), household nonresponse, and the
exclusion of phoneless households. The survey also tracks progress towards Healthy
People 2020 and Healthy
People 2030 goals.
CDC
changed the way that NIS results are reported starting in 2019. In the past,
results were reported for children 19-35 months of age at the time of the
survey. Now, results for most vaccines are reported at 24 months of age by
birth year. Exemptions to this are the hepatitis B birth dose and Rotavirus
vaccines which are reported at younger ages because they are completed before
24 months.
Coverage
rates were reported for the U.S., Texas, and the selected areas of the City of
Houston, Bexar County, El Paso County, and Dallas County.
Survey Sample
2020 NIS-Child data
was collected from 2018 to 2020, resulting in a national sample size of 29,114
children born in 2017-2018 with adequate provider data. Additionally,
these estimates reflect vaccinations that occurred mostly before
the COVID-19 pandemic. For data collected in 2020, there was a low
interview response rate (22.5%) and adequate provider data was available for
only 54.2% of those with completed interviews.
Vaccines
Included
The NIS collects information on the following
vaccine series to assess the percent of children that are up to date with
routinely recommended vaccinations:
- Diphtheria
and tetanus toxoids and acellular pertussis vaccine (DTaP/DT/DTP)
- Poliovirus
vaccine (Polio)
- Measles
or Measles-Mumps-Rubella vaccine (MMR)
- Haemophilus
influenzae
type b vaccine (Hib)
- Hepatitis
B vaccine (HepB)
- Varicella
vaccine (Var)
- Pneumococcal
conjugate vaccine (PCV)
- Hepatitis
A vaccine (HepA)
- Rotavirus
vaccine
- Influenza
(Flu)
- 4:3:1:3*:3:1:4
series
o
≥4
doses of DTaP
o
≥3
doses of Polio
o
≥1
dose of MMR
o
≥3
doses of Hib (*3 or 4 doses depending on vaccine type)
o
≥3
doses of HepB
o
≥1
dose of Var
o
≥4
doses of PCV
The
4:3:1:3*:3:1:4 series reflects vaccine coverage for seven key vaccines
combined. It measures overall compliance with the recommendations of the
Advisory Committee on Immunization Practices (ACIP) for young children.
NIS
Coverage Estimates

a Coverage
estimates are at 24 months unless otherwise noted (i.e. rotavirus vaccine
coverage assessed at 8 months)
b Data for the 2015 birth year are from survey years 2016, 2017, and
2018; data for the 2016 birth year are from survey years 2017, 2018, and 2019;
data for the 2017 birth year are from survey years 2018, 2019, and 2020; data
for the 2018 birth year are considered preliminary and come from survey years
2019 and 2020 (data from survey year 2021 are not yet available).
c Full
series (FS) of either 3 or 4 doses of Hib
conjugate vaccine, depending on vaccine type
d Either ≥2 or ≥3 doses of rotavirus
vaccine, depending on product used, by 8 months of age
e Doses
must be at least 24 days apart (four weeks, with a four-day grace period)
f
4:3:1:3:3:1:4 includes 4+ DTaP (diphtheria, tetanus, and acellular pertussis),
3+polio, 1+MMR (measles, mumps and rubella), 3 or 4 doses Hib, depending on
vaccine type, 3+Hep B, 1+varicella, and 4+PCV
g Statistically
significant difference from U.S estimate (p<0.05)
 - No footnotes.jpg)
a Coverage
estimates are at 24 months unless otherwise noted (i.e. rotavirus vaccine
coverage assessed at 8 months)
b Data for
the 2015 birth year are from survey years 2016, 2017, and 2018; data for the
2016 birth year are from survey years 2017, 2018, and 2019; data for the 2017
birth year are from survey years 2018, 2019, and 2020; data for the 2018 birth
year are considered preliminary and come from survey years 2019 and 2020 (data
from survey year 2021 are not yet available).
c Full series (FS)
of either 3 or 4 doses of Hib
conjugate vaccine, depending on vaccine type
d Either ≥2 or ≥3 doses of rotavirus
vaccine, depending on product used
e Doses must be at
least 24 days apart (four weeks, with a four-day grace period)
f 4:3:1:3:3:1:4
includes 4+ DTaP (diphtheria, tetanus, and acellular pertussis), 3+polio, 1+MMR
(measles, mumps and rubella), 3 or 4 doses Hib, depending on vaccine type,
3+Hep B, 1+varicella, and 4+PCV
g Vaccination
coverage estimates for some vaccines were not included due to small sample
sizes (-)

a Coverage
estimates are at 24 months unless otherwise noted (i.e. rotavirus vaccine
coverage assessed at 8 months)
b Data for the 2018
birth year are considered preliminary and come from survey years 2019 and 2020
c Full series (FS)
of either 3 or 4 doses of Hib
conjugate vaccine, depending on vaccine type
f 4:3:1:3:3:1:4
includes 4+ DTaP (diphtheria, tetanus, and acellular pertussis), 3+polio, 1+MMR
(measles, mumps and rubella), 3 or 4 doses Hib, depending on vaccine type,
3+Hep B, 1+varicella, and 4+PCV

a Coverage
estimates are at 24 months unless otherwise noted and for children born
2017-2018 (i.e. rotavirus vaccine coverage assessed at 8 months)
b Data for the 2018
birth year are considered preliminary and come from survey years 2019 and 2020
c Full series (FS)
of either 3 or 4 doses of Hib conjugate
vaccine, depending on vaccine type
f 4:3:1:3:3:1:4
includes 4+ DTaP (diphtheria, tetanus, and acellular pertussis), 3+polio, 1+MMR
(measles, mumps and rubella), 3 or 4 doses Hib, depending on vaccine type,
3+Hep B, 1+varicella, and 4+PCV
For access to the full dataset, please see the
CDC Data and Documentation for NIS Surveys page.
Archived Survey Results
View survey results from prior years: